- |||||||||| carbamazepine / Generic mfg.
Review, Journal: Neuropharmacology of Antiseizure Drugs. (Pubmed Central) - Jan 15, 2022
Antiseizure drugs have different pharmacologic profiles that should be considered when selecting and prescribing these agents for epilepsy. These include pharmacokinetic properties, propensity for drug-drug interactions, and adverse effects.
- |||||||||| zonisamide / Generic mfg., primidone / Generic mfg., levetiracetam / Generic mfg.
Clinical, Journal: Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy. (Pubmed Central) - Jan 12, 2022
JME), the estimated risk of clinically relevant seizure aggravation under treatment with lamotrigine was 3.7 % (1.8 % for zonisamide and 0.8 % for levetiracetam). In conclusion, clinical significant aggravation of seizure frequency is common in lamotrigine-treated JME patients but rare in patients with other GGE subsyndromes or under treatment with other recommended anti-seizure medication.
- |||||||||| zonisamide / Generic mfg.
Clinical, Retrospective data, Journal: Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials. (Pubmed Central) - Jan 7, 2022
Zonisamide 25 mg and 50 mg significantly reduced the axial symptom score at week 12 compared with placebo (p < 0.01 and p < 0.001, respectively, by mixed model of repeated measures). Our findings indicate that zonisamide may improve axial symptoms in DLB with parkinsonism and, thus, may potentially reduce the risk of falls and improve quality of life in this vulnerable patient population.
- |||||||||| carbocisteine / Generic mfg., zonisamide / Generic mfg., ambroxol oral / Generic mfg.
Journal: Occupational Exposure of Pharmacists to Drugs during the Preparation of Powder Drugs in Dispensing Pharmacies (Pubmed Central) - Jan 4, 2022
First, we determined frequently prescribed tipepidine hibenzate and ambroxol hydrochloride suspended in the air of the dispensing room...Analysis of the active ingredients of the drugs used in the preparation revealed that eight drugs, including bethanechol, l-carbocisteine, and zonisamide, were detected in the range of 1.5-1220 μg/m...When the amount of drug powder collected on filters that is either covered with or without a medical mask was compared, the covered filter exhibited reduced drug powder accumulation to less than 10% the amount collected on the uncovered filter. The present data suggested that a medical mask might decrease the drug dust allergies in dispensing pharmacists.
- |||||||||| phenytoin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Journal: Screening for Activity Against AMPA Receptors Among Anticonvulsants-Focus on Phenytoin. (Pubmed Central) - Dec 27, 2021
The interest in AMPA receptors as a target for epilepsy treatment increased substantially after the approval of perampanel, a negative AMPA receptor allosteric antagonist, for the treatment of partial-onset seizures and generalized tonic-clonic seizures...Lamotrigine, topiramate, levetiracetam, felbamate, carbamazepine, tiagabin, vigabatrin, zonisamide, and gabapentin in 100-µM concentration were practically inactive against both major subtypes of AMPARs, while phenytoin reversibly inhibited them with IC50 of 30 ± 4 μM and 250 ± 60 µM for CI-AMPARs and CP-AMPARs, respectively...Here we have shown for the first time that phenytoin inhibits CI-AMPARs with similar potency. Thus, AMPAR inhibition by phenytoin may contribute to its anticonvulsant properties as well as its side effects.
- |||||||||| neflamapimod (VX-745) / EIP Pharma
Review, Journal: Therapeutic trials and Dementia with Lewy bodies: a systematic review of the literature. (Pubmed Central) - Dec 24, 2021
Compared to other cognitive neurodegenerative diseases, therapeutic research is largely insufficient, although the proportion of positive trials is significant. Effective treatment to modify the course of the disease would have significant consequences for patients and their relatives.
- |||||||||| Clinical, Review, Journal: Therapeutic Options for Childhood Absence Epilepsy. (Pubmed Central) - Dec 24, 2021
In the case of first line treatment failure, after two monotherapies it is usual to start a bi-therapy. In the case of absence seizures that are refractory to traditional treatment, other antiepileptic drugs may be introduced such as levetiracetam, topiramate and zonisamide.
- |||||||||| zonisamide / Generic mfg.
Reciprocal control of obesity and anxiety-depressive disorder via a GABA and serotonin neural circuit (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6982;
To gain further translational insights, we revealed that combined treatment of zonisamide (enhancing the GABA A R-α5 signaling) and granisetron (a selective 5-HT 3 R antagonist) alleviates mental dysfunction and yields a robust reversal of diet-induced obesity by reducing total calorie intake and altering food preference towards a healthy low-fat diet. Our results unveil a neural mechanism for a reciprocal control of appetite and mental states, which culminates in a novel zonisamide-granisetron cocktail therapy for potential tackling the psychosis-obesity comorbidity.; Grant Support: Pew Charitable Trust; NIH Grant R01DK093587; NIH Grant 1R56DK109194; ADA Grants 1-17-PDF-138; NIH Grant R01DK117281; ADA Grants 7-13-JF-61; IDDRC Grant Number U54HD083092; NIH Grant 1R01DK109194; NIH COBRE grant P20 GM135002; NIH Grant R01DK101379; USDA/CRIS grants 3092-5-001-059
- |||||||||| zonisamide / Generic mfg.
Zonisamide pre-treatment alleviates oxaliplatin-induced dorsal root ganglion neuron death in vitro (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_3038;
These findings suggest that zonisamide alleviates OHP-induced DRG neuronal cell injury and death via stimulating PI3K signaling pathway. Zonisamide pre-treatment may be efficacious against the neurotoxic adverse effects of OHP.; Grant Support: JSPS KAKENHI 20K07027; JSPS KAKENHI 20K07773; Research funding from Sumitomo Dainippon Pharma Co., Ltd., Japan
- |||||||||| pregabalin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Setting a new platform for antiseizure drug testing: a mouse model with impaired mitochondrial oxidative phosphorylation recapitulates the human drug-resistant epilepsy. (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_972;
According to our observations, the rotenone kindling model shows significant resistance (P<0.05) to Lamotrigine (15mg/kg), Levetiracetam (40mg/kg), Carbamazepine (40mg/kg), Zonisamide (100mg/kg), Gabapentin (224mg/kg), Pregabalin (30mg/kg), Phenytoin (35mg/kg), Topiramate (300mg/kg), Valproate (200mg/kg), and two drug combinations (lamotrigine + aforementioned drugs), with less than 10% mortality. Pre-clinical drug testing through the rotenone-kindling model may uncover more effective drug therapies for the management of drug-resistant epilepsy because the rotenone-kindling model shows resistance to third-generation antiseizure drugs as well as their two-drug combinations.; Grant Support: IBRO International Travel Grant; Senior Research Fellowship (ICMR Grant 45/01/2019-PHA/BMS)
- |||||||||| carbamazepine / Generic mfg.
Biomarker, Review, Journal: Developing a gene panel for pharmacoresistant epilepsy: a review of epilepsy pharmacogenetics. (Pubmed Central) - Dec 16, 2021
Our work provides support for a specific pharmacoresistant epilepsy gene panel to assist antiseizure medicine selection, enabling personalized approaches to treatment. Future efforts will seek to include this panel in genomic analyses of pharmacoresistant patients, to determine clinical utility and patient treatment responses.
- |||||||||| zonisamide / Generic mfg.
Journal: Zonisamide Use With Continuous Renal Replacement Therapy. (Pubmed Central) - Dec 16, 2021
Future efforts will seek to include this panel in genomic analyses of pharmacoresistant patients, to determine clinical utility and patient treatment responses. No abstract available
- |||||||||| zonisamide / Generic mfg.
Journal: Teratogenic effects of zonisamide. (Pubmed Central) - Dec 16, 2021
The restored urine and serum profile of various parameters to normal physiological levels suggests that the A. parviflora has potential antioxidant and repairing potential in renal disorders. No abstract available
- |||||||||| Fycompa (perampanel) / Eisai, lamotrigine liquid oral suspension / OWP Pharma
Novel Gene Abnormality in Epilepsy with Myoclonic-Astatic Seizures (Doose Syndrome) () - Dec 12, 2021 - Abstract #AES2021AES_1716;
Our patient does not present with the classic history, physical, and imaging findings associated with that disorder. Such findings include rapidly progressive encephalopathy, feeding difficulties, progressive microcephaly, lens subluxation, and loss of gray-white matter in the cerebral cortex & basal ganglia on MRI imaging.
- |||||||||| Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Effects of Eslicarbazepine Acetate on Bone Density and on Bone Metabolism () - Dec 12, 2021 - Abstract #AES2021AES_1469;
Neither osteodensitometry nor bone metabolism parameters showed significant group effects after one year of treatment with eslicarbazepine acetate. Individual fluctuations were observed, however, which may warrant monitoring particularly in patients under polytherapy.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Pregnancy and Neonatal Outcomes in Women with Epilepsy Exposed to Lacosamide During Pregnancy () - Dec 12, 2021 - Abstract #AES2021AES_1394;
Women in our cohort were all on polytherapy which might have contributed to the increased rate of miscarriage as previously reported in published literature. Conclusions regarding a causal relationship between LCM and miscarriage could thus be misleading based on our data alone.
- |||||||||| Xcopri (cenobamate) / SK Bio, Angelini Group
Interaction Between Cenobamate and Clobazam: A Single Center Clinical Experience () - Dec 12, 2021 - Abstract #AES2021AES_806;
It is rarely practical to obtain CLB/N-CLB levels, thus a preemptive decrease in CLB after CNB initiation should be strongly considered for CNB dosages of 100 mg and above. While seizure reduction was present in our small cohort, a CLB reduction of 50% or more was required to resolve toxicity.
- |||||||||| midazolam hydrochloride / Generic mfg., carbamazepine / Generic mfg., voriconazole / Generic mfg.
Clinical, PK/PD data, Review, Journal: A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children. (Pubmed Central) - Dec 1, 2021
Voriconazole might also be predicted to increase levels of cannabidiol, CBZ, lacosamide, midazolam, and zonisamide. DDIs between ASMs and some antiviral agents are potentially even more frequent and clinically relevant.
- |||||||||| risperidone / Generic mfg.
Journal: Interictal psychosis of epilepsy (Pubmed Central) - Nov 29, 2021
In practice, atypical neuroleptics with few motor side effects such as risperidone can be used as first choice, given the low propensity for drug-drug interactions and the low seizure risk, with the added suggestion to start low and go slow. Clozapine could be prescribed in selected cases.
- |||||||||| neflamapimod (VX-745) / EIP Pharma
Review, Journal: Therapeutic trials in dementia with Lewy bodies: a systematic review of the literature (Pubmed Central) - Nov 29, 2021
Compared to other cognitive neurodegenerative diseases, therapeutic research is largely insufficient, whereas the proportion of positive trials is important. An effective disease modifying would have strong consequences for the patient and the relatives.
- |||||||||| zonisamide / Generic mfg.
Zonisamide Treatment of Alcohol Use Disorder ([VIRTUAL]) - Nov 28, 2021 - Abstract #ACNP2021ACNP_1415;
An effective disease modifying would have strong consequences for the patient and the relatives. Zonisamide is an efficacious treatment for AUD and appears to have greater efficacy among men than women, although this and other potential predictors of the response to zonisamide treatment warrant further study.
- |||||||||| zonisamide / Generic mfg.
Zonisamide Treatment of Alcohol Use Disorder (Exhibit Hall C) - Nov 28, 2021 - Abstract #ACNP2021ACNP_255;
Zonisamide is an efficacious treatment for AUD and appears to have greater efficacy among men than women, although this and other potential predictors of the response to zonisamide treatment warrant further study. Zonisamide is an efficacious treatment for AUD and appears to have greater efficacy among men than women, although this and other potential predictors of the response to zonisamide treatment warrant further study.
- |||||||||| Ztalmy (ganaxolone oral) / Marinus
Review, Journal: Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. (Pubmed Central) - Nov 24, 2021
Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate and ganaxolone...Because LGS is not a single entity, tailoring of treatment is needed as opposed to a 'one size fits all' approach. Further research is needed into the underlying aetiologies and pathophysiology of LGS, together with advancements in treatments that encompass the spectrum of seizures associated with this complex syndrome.
- |||||||||| zonisamide / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease (clinicaltrials.gov) - Nov 23, 2021
P4, N=20, Suspended,
Further research is needed into the underlying aetiologies and pathophysiology of LGS, together with advancements in treatments that encompass the spectrum of seizures associated with this complex syndrome. Trial completion date: Dec 2018 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Apr 2018 --> Dec 2022
- |||||||||| zonisamide / Generic mfg.
Journal: Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template. (Pubmed Central) - Nov 21, 2021
Typical CYP3A7 substrates such as zonisamide and retinoic acids took their placements without occupying a left side region of Template for their metabolisms...Altered extent of IJK-Interaction or localization of a specific residue at the left-side would thus explain distinct catalytic properties of CYP3A7 on Template. These data suggest the alteration of each one of Template region, from CYP3A4 Template, led to the distinct catalytic properties of CYP3A5 and CYP3A7 forms.
- |||||||||| bumetanide / Generic mfg., carbamazepine / Generic mfg.
Preclinical, Journal: Pathology-selective antiepileptic effects in the focal freeze-lesion rat model of malformation of cortical development. (Pubmed Central) - Nov 11, 2021
Our work adds evidence for the functional relevance of chloride homeostasis in the pathophysiology of microgyrus formation as represented in the focal freeze-lesion model. Further studies in different MCD models and human tissue will be required to validate the effects across different MCD subtypes and species and to assess the translational value of our findings.
- |||||||||| Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Journal: Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes. (Pubmed Central) - Nov 6, 2021
Newer ASMs such as brivaracetam and perampanel seem to be promising options. Well-conducted clinical trials aimed to evaluate the efficacy of alternative monotherapy (beyond ESX, VPA or LTG) or combination of ASMs on difficult-to-treat TAs, are warranted.
- |||||||||| amantadine / Generic mfg.
Review, Journal: Management of Tardive Syndrome: Medications and Surgical Treatments. (Pubmed Central) - Oct 30, 2021
Anti-dyskinetic drugs are separated into 3 tiers: 1) vesicular monoamine transporter type 2 inhibitors, which have level A evidence, are approved for use in TS and are recommended first-choice agents; 2) drugs with lower level of evidence for efficacy including clonazepam, Ginkgo biloba, and amantadine; and 3) drugs that have the potential to be beneficial, but currently have insufficient evidence including levetiracetam, piracetam, vitamin B, melatonin, baclofen, propranolol, zolpidem, and zonisamide...Current therapies, though improved, are symptomatic. Next steps should focus on the prevention and reversal of the pathogenic process.
- |||||||||| amantadine / Generic mfg.
Review, Journal: Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. (Pubmed Central) - Oct 22, 2021
Long-acting formulations of amantadine are approved for treating dyskinesia...For example, CX-8998 (a calcium channel modulator) is being evaluated for PD tremor and rivastigmine may improve gait dysfunction in PD. Drug repurposing continues to be a key strategy for non-dopaminergic targets in PD, but the field needs to increase discovery and availability of such drugs.
- |||||||||| carbamazepine / Generic mfg.
[VIRTUAL] Total Daily Dosage of Anti-Epileptic Drugs in Women with Epilepsy with Subsequent Pregnancies () - Oct 21, 2021 - Abstract #ANA2021ANA_222;
This variation may reflect differences in the timing of level testing, variability in practitioner dosage change during different pregnancies amongst other factors. The doses used during an initial pregnancy may be useful in guiding dose management in successive pregnancies, but frequent testing of levels may still be needed.
- |||||||||| zonisamide / Generic mfg., levetiracetam / Generic mfg.
Clinical, P4 data, Journal, HEOR, Head-to-Head: The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. (Pubmed Central) - Oct 16, 2021
P4
These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy. Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials.
- |||||||||| Clinical, Journal: Clinical characteristics of KCNQ2 encephalopathy. (Pubmed Central) - Oct 7, 2021
Sodium channel blockers are effective in seizure control in these patients with KCNQ2 encephalopathy. Early recognition of KCNQ2 encephalopathy and early use of sodium channel blockers might be helpful in seizure control.
|
